ATYR vs. TERN, AVXL, VERV, SAGE, CMPS, CTNM, ALT, SLRN, NGNE, and GHRS
Should you be buying Atyr PHARMA stock or one of its competitors? The main competitors of Atyr PHARMA include Terns Pharmaceuticals (TERN), Anavex Life Sciences (AVXL), Verve Therapeutics (VERV), Sage Therapeutics (SAGE), COMPASS Pathways (CMPS), Contineum Therapeutics (CTNM), Altimmune (ALT), Acelyrin (SLRN), Neurogene (NGNE), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry.
Terns Pharmaceuticals (NASDAQ:TERN) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
In the previous week, Terns Pharmaceuticals had 1 more articles in the media than Atyr PHARMA. MarketBeat recorded 7 mentions for Terns Pharmaceuticals and 6 mentions for Atyr PHARMA. Terns Pharmaceuticals' average media sentiment score of 0.76 beat Atyr PHARMA's score of 0.15 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.
Atyr PHARMA has lower revenue, but higher earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Atyr PHARMA, indicating that it is currently the more affordable of the two stocks.
Terns Pharmaceuticals presently has a consensus target price of $13.50, suggesting a potential upside of 72.86%. Atyr PHARMA has a consensus target price of $20.00, suggesting a potential upside of 963.83%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Terns Pharmaceuticals.
Terns Pharmaceuticals' return on equity of -39.58% beat Atyr PHARMA's return on equity.
98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Terns Pharmaceuticals has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.
Terns Pharmaceuticals received 32 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 59.68% of users gave Terns Pharmaceuticals an outperform vote.
Summary
Terns Pharmaceuticals beats Atyr PHARMA on 10 of the 17 factors compared between the two stocks.
Get Atyr PHARMA News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atyr PHARMA Competitors List
Related Companies and Tools
